Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $10.3 million.

  • Allogene Therapeutics' Other Non-Current Assets changed negligibly% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $10.3 million for FY2024, which is negligibly% changed negligibly from last year.
  • Allogene Therapeutics' Other Non-Current Assets amounted to $10.3 million in Q3 2025, which was down 0.00% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Other Non-Current Assets ranged from a high of $10.3 million in Q4 2021 and a low of $9.4 million during Q1 2021.
  • Its 3-year average for Other Non-Current Assets is $10.3 million, with a median of $10.3 million in 2025.
  • Data for Allogene Therapeutics' Other Non-Current Assets shows a peak YoY spiked of 119.80% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Other Non-Current Assets stood at $10.3 million in 2021, then remained steady at $10.3 million in 2022, then remained steady at $10.3 million in 2023, then remained steady at $10.3 million in 2024, then remained steady at $10.3 million in 2025.
  • Its Other Non-Current Assets stands at $10.3 million for Q3 2025, versus $10.3 million for Q2 2025 and $10.3 million for Q1 2025.